Eli Lilly (LLY) Updates on Baricitinib and Ixekizumab Improve Pipeline Visibility - Cowen
Tweet Send to a Friend
Cowen maintained an Outperform rating on Eli Lilly (NYSE: LLY) with a price target of $85. Comments follow an investor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
